Literature DB >> 80429

Inosiplex, a stimulating agent for normal human T cells and human leukocytes.

J Wybran, A Govaerts, T Appelboom.   

Abstract

The influence of inosiplex upon various in vitro leucocyte assays was studied in normal individuals. It was found that the drug increases the response of bidirectional and unidirectional mixed lymphocyte cultures at concentrations of 200, 300, and 500 microgram/ml. It also significantly increases the percentage of active T rosettes (concentration range: 50 to 500 microgram/ml) and the percentage of autologous red cell T rosettes (concentration: 100 microgram/ml). In contrast, inosiplex did not modify the percentage of total T rosettes and EAC rosettes. Inosiplex increases the number of nonadherent leucocytes in the leucocyte adherence inhibition test at a concentration range between 100 and 300 microgram/ml. Finally, inosiplex also increases the percentage of monocytes phagocytizing yeast at a concentration between 50 and 500 microgram/ml. These data indicate that inosiplex enhances the function of normal human T cells, monocytes, and possibly neutrophils. Therefore inosiplex appears to have immunostimulant properties.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 80429

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Depressed 3H-thymidine incorporation by measles infected mononuclear cells can be corrected by treatment with isoprinosine or 5-fluoro-2-deoxyuridine.

Authors:  R Lomnitzer; A R Rabson
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

2.  New approaches to immunotherapy: thymomimetic drugs.

Authors:  S Specter; J W Hadden
Journal:  Springer Semin Immunopathol       Date:  1985

Review 3.  Ribavirin and inosiplex: a review of their present status in viral diseases.

Authors:  T W Chang; R C Heel
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

4.  Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases.

Authors:  T Nakamura; N Miyasaka; R M Pope; N Talal; I J Russell
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

5.  Combined therapy with isoprinosine and CO2 laser microsurgery for the treatment of laryngeal papillomatosis.

Authors:  J Elö; Z Máté
Journal:  Arch Otorhinolaryngol       Date:  1988

6.  Modulation of T- and B-lymphocyte functions by isoprinosine in homosexual subjects with prodromata and in patients with acquired immune deficiency syndrome (AIDS).

Authors:  P H Tsang; K Tangnavarad; S Solomon; J G Bekesi
Journal:  J Clin Immunol       Date:  1984-11       Impact factor: 8.317

Review 7.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

Review 8.  Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course.

Authors:  Jiří Beran; Marián Špajdel; Jiří Slíva
Journal:  Viruses       Date:  2021-11-09       Impact factor: 5.048

9.  Genotoxicity and Mutagenicity of Inosine Pranobex.

Authors:  Sylwia Tobólska; Sylwia Terpiłowska; Jerzy Jaroszewski; Andrzej Krzysztof Siwicki
Journal:  J Vet Res       Date:  2018-10-24       Impact factor: 1.744

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.